INBIOGEN Co., Ltd. (KRX:101140)
South Korea · Delayed Price · Currency is KRW 8,890.00
+90.00 (1.02%)
At close: Apr 24, 2026
INBIOGEN Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 6,297 | 7,041 | 6,241 | 10,420 | 10,481 |
Other Revenue | 0 | -0 | 0 | - | - |
| 6,297 | 7,041 | 6,241 | 10,420 | 10,481 | |
Revenue Growth (YoY) | -10.57% | 12.82% | -40.11% | -0.58% | 2.57% |
Cost of Revenue | 6,681 | 6,413 | 4,933 | 8,447 | 8,652 |
Gross Profit | -384.38 | 628.51 | 1,308 | 1,972 | 1,829 |
Selling, General & Admin | 3,640 | 5,540 | 5,727 | 6,643 | 8,124 |
Research & Development | - | - | 8.19 | 3.67 | 24.6 |
Amortization of Goodwill & Intangibles | 113.19 | 195.42 | 166.6 | 150.9 | 114.43 |
Other Operating Expenses | 39.61 | 59.69 | 577.86 | 124.04 | 158.74 |
Operating Expenses | 3,948 | 6,715 | 7,471 | 7,942 | 9,975 |
Operating Income | -4,333 | -6,087 | -6,164 | -5,969 | -8,146 |
Interest Expense | -78.45 | -51.35 | -262.15 | -3,686 | -3,830 |
Interest & Investment Income | 864.37 | 924.91 | 1,289 | 1,823 | 1,839 |
Earnings From Equity Investments | - | - | -32,457 | 42,777 | -5,062 |
Currency Exchange Gain (Loss) | - | - | - | - | -13.77 |
Other Non Operating Income (Expenses) | 110.07 | 959.14 | 10,750 | 16,875 | 10,421 |
EBT Excluding Unusual Items | -3,437 | -4,254 | -26,844 | 51,819 | -4,792 |
Gain (Loss) on Sale of Investments | 3,009 | 21,537 | 39,032 | -178,976 | 115,995 |
Gain (Loss) on Sale of Assets | 61.39 | -168.16 | -64.79 | - | -138.43 |
Asset Writedown | -1,052 | -992.37 | - | - | - |
Other Unusual Items | - | - | -263.58 | -6,745 | - |
Pretax Income | -1,419 | 16,122 | 11,859 | -133,902 | 111,064 |
Income Tax Expense | - | - | - | -16,953 | 16,939 |
Earnings From Continuing Operations | -1,419 | 16,122 | 11,859 | -116,949 | 94,125 |
Earnings From Discontinued Operations | - | - | -514.7 | -268.78 | - |
Net Income | -1,419 | 16,122 | 11,344 | -117,218 | 94,125 |
Net Income to Common | -1,419 | 16,122 | 11,344 | -117,218 | 94,125 |
Net Income Growth | - | 42.12% | - | - | - |
Shares Outstanding (Basic) | - | 10 | 9 | 4 | 3 |
Shares Outstanding (Diluted) | - | 10 | 9 | 4 | 3 |
Shares Change (YoY) | - | 17.33% | 134.70% | 21.34% | 44.57% |
EPS (Basic) | - | 1614.69 | 1333.01 | -32327.53 | 35054.16 |
EPS (Diluted) | - | 1614.69 | 1333.01 | -32327.53 | 31498.90 |
EPS Growth | - | 21.13% | - | - | - |
Free Cash Flow | -5,597 | -117.41 | -1,077 | -11,636 | -9,430 |
Free Cash Flow Per Share | - | -11.76 | -126.51 | -3209.03 | -3155.62 |
Gross Margin | -6.10% | 8.93% | 20.95% | 18.93% | 17.45% |
Operating Margin | -68.81% | -86.45% | -98.77% | -57.29% | -77.73% |
Profit Margin | -22.53% | 228.98% | 181.77% | -1124.99% | 898.07% |
Free Cash Flow Margin | -88.88% | -1.67% | -17.25% | -111.67% | -89.97% |
EBITDA | -3,969 | -5,030 | -4,940 | -4,531 | -7,029 |
EBITDA Margin | -63.04% | -71.43% | -79.15% | -43.49% | -67.07% |
D&A For EBITDA | 363.49 | 1,057 | 1,224 | 1,438 | 1,117 |
EBIT | -4,333 | -6,087 | -6,164 | -5,969 | -8,146 |
EBIT Margin | -68.81% | -86.45% | -98.77% | -57.29% | -77.73% |
Effective Tax Rate | - | - | - | - | 15.25% |
Advertising Expenses | 72.44 | 26.66 | 31.43 | 65.86 | 66.51 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.